These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 35234370)
21. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552 [TBL] [Abstract][Full Text] [Related]
22. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334 [TBL] [Abstract][Full Text] [Related]
23. Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway. Li B; Zhang Y; Yin R; Zhong W; Chen R; Yan J Mediators Inflamm; 2020; 2020():1649453. PubMed ID: 33162828 [TBL] [Abstract][Full Text] [Related]
24. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related]
25. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. Yokoyama Y; Xin B; Shigeto T; Mizunuma H J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458 [TBL] [Abstract][Full Text] [Related]
27. NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance. Liu J; Wang H; Wan H; Yang J; Gao L; Wang Z; Zhang X; Han W; Peng J; Yang L; Hong L Cell Death Dis; 2024 Sep; 15(9):661. PubMed ID: 39256367 [TBL] [Abstract][Full Text] [Related]
28. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade. Park J; Park SY; Kim JH Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704 [TBL] [Abstract][Full Text] [Related]
30. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Li D; Williams JI; Pietras RJ Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639 [TBL] [Abstract][Full Text] [Related]
31. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling. Huang SW; Lien JC; Kuo SC; Huang TF Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319 [TBL] [Abstract][Full Text] [Related]
32. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis. Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054 [TBL] [Abstract][Full Text] [Related]
33. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. Devapatla B; Sharma A; Woo S PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070 [TBL] [Abstract][Full Text] [Related]
34. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Bharti R; Dey G; Khan D; Myers A; Huffman OG; Saygin C; Braley C; Richards E; Sangwan N; Willard B; Lathia JD; Fox PL; Lin F; Jha BK; Brown JM; Yu JS; Dwidar M; Joehlin-Price A; Vargas R; Michener CM; Longworth MS; Reizes O Mol Cancer; 2024 Jun; 23(1):121. PubMed ID: 38853277 [TBL] [Abstract][Full Text] [Related]
35. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M; Bai T; Tsang BK Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180 [TBL] [Abstract][Full Text] [Related]
36. FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming. Bhattacharya R; Ray Chaudhuri S; Roy SS J Cell Biochem; 2018 Nov; 119(10):8174-8189. PubMed ID: 29904943 [TBL] [Abstract][Full Text] [Related]
37. Zebrafish WNK lysine deficient protein kinase 1 (wnk1) affects angiogenesis associated with VEGF signaling. Lai JG; Tsai SM; Tu HC; Chen WC; Kou FJ; Lu JW; Wang HD; Huang CL; Yuh CH PLoS One; 2014; 9(8):e106129. PubMed ID: 25171174 [TBL] [Abstract][Full Text] [Related]
38. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231 [TBL] [Abstract][Full Text] [Related]
39. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558 [TBL] [Abstract][Full Text] [Related]
40. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis. Dewangan J; Kaushik S; Rath SK; Balapure AK Life Sci; 2018 Jan; 193():9-19. PubMed ID: 29196053 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]